Apolipoprotein genotype for prediction of Alzheimer's disease in older Japanese: The hisayama study

Journal of the American Geriatrics Society

Volumn 59, Issue 6, 2011, Pages 1074-1079

  Ohara, Tomoyuki ^a   Ninomiya, Toshiharu ^a   Kubo, Michiaki ^b   Hirakawa, Yoichiro ^a   Doi, Yasufumi ^a   Hata, Jun ^a   Iwaki, Toru ^a   Kanba, Shigenobu ^a   Kiyohara, Yutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

Alzheimer's disease; APOE; cohort study; dementia; vascular dementia

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; CHOLESTEROL; DNA; GLYCOSYLATED HEMOGLOBIN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ALLELE; ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMMUNITY SAMPLE; DEMENTIA; EDUCATIONAL STATUS; EXERCISE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HAZARD RATIO; HETEROZYGOSITY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIINFARCT DEMENTIA; NEUROIMAGING; PREDICTION; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SYSTOLIC BLOOD PRESSURE;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; DEMENTIA, VASCULAR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOTYPE; HEALTH BEHAVIOR; HETEROZYGOTE DETECTION; HUMANS; JAPAN; LIFE STYLE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 79958831449     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03405.x     Document Type: Article

References (27)

1. Tschanz JT, Corcoran C, Skoog I, et al,. Dementia: The leading predictor of death in a defined elderly population: The Cache County Study. Neurology 2004; 62: 1156-1162. (Pubitemid 38456511)
2. Suh GH, Shah A., A review of the epidemiological transition in dementia-cross-national comparisons of the indices related to Alzheimer's disease and vascular dementia. Acta Psychiatr Scand 2001; 104: 4-11. (Pubitemid 32532323)
3. Sekita A, Ninomiya T, Tanizaki Y, et al,. Trends in prevalence of Alzheimer's disease and vascular dementia in a Japanese community: The Hisayama Study. Acta Psychiatr Scand 2010; 122: 319-325.
4. Matsui Y, Tanizaki Y, Arima H, et al,. Incidence and survival of dementia in a general population of Japanese elderly: The Hisayama Study. J Neurol Neurosurg Psychiatry 2009; 80: 366-370.
5. Yamada M, Mimori Y, Kasagi F, et al,. Incidence of dementia, Alzheimer disease, and vascular dementia in a Japanese population: Radiation Effects Research Foundation adult health study. Neuroepidemiology 2008; 30: 152-160. (Pubitemid 351667795)
6. Miech RA, Breitner JC, Zandi PP, et al,. Incidence of AD may decline in the early 90 s for men, later for women: The Cache County Study. Neurology 2002; 58: 209-218. (Pubitemid 34084209)
7. Fratiglioni L, Launer LJ, Andersen K, et al,. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S10-S15. (Pubitemid 30390599)
8. Purnell C, Gao S, Callahan CM, et al,. Cardiovascular risk factors and incident Alzheimer disease: A systematic review of the literature. Alzheimer Dis Assoc Disord 2009; 23: 1-10.
9. Havlik RJ, Izmirlian G, Petrovitch H, et al,. APOE-É4 predicts incident AD in Japanese-American men: The Honolulu-Asia Aging Study. Neurology 2000; 54: 1526-1529. (Pubitemid 30210480)
10. Borenstein AR, Wu Y, Mortimer JA, et al,. Developmental and vascular risk factors for Alzheimer's disease. Neurobiol Aging 2005; 26: 325-334. (Pubitemid 40082715)
11. Mayeux R, Saunders AM, Shea S, et al,. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998; 338: 506-511. (Pubitemid 28103134)
12. Kardaun JW, White L, Resnick HE, et al,. Genotypes and phenotypes for apolipoprotein E and Alzheimer disease in the Honolulu-Asia Aging Study. Clin Chem 2000; 46: 1548-1554.
13. Yoshitake T, Kiyohara Y, Kato I, et al,. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: The Hisayama Study. Neurology 1995; 45: 1161-1168.
14. Ohmura T, Ueda K, Kiyohara Y, et al,. Prevalence of type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: The Hisayama Study. Diabetologia 1993; 36: 1198-1203. (Pubitemid 23314572)
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd Ed., Revised. Washington, DC: American Psychiatric Association, 1987.
16. McKhann G, Drachman D, Folstein M, et al,. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944. (Pubitemid 14076461)
17. Román GC, Tatemichi TK, Erkinjuntti T, et al,. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-260. (Pubitemid 23060253)
18. Fujimi K, Sasaki K, Noda K, et al,. Clinicopathological outline of dementia with Lewy bodies applying the revised criteria: The Hisayama Study. Brain Pathol 2008; 18: 317-325. (Pubitemid 351782854)
19. Ohnishi Y, Tanaka T, Ozaki K, et al,. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 2001; 46: 471-477. (Pubitemid 32744120)
20. DeLong ER, DeLong DM, Clarke-Pearson DL., Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988; 44: 837-845.
21. Pencina MJ, D'Agostino RB Sr., D'Agostino RB Jr., et al,. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172; discussion 207-212. (Pubitemid 351193639)
22. Hlatky MA, Greenland P, Arnett DK, et al,. Criteria for evaluation of novel markers of cardiovascular risk: A scientific statement from the American Heart Association. Circulation 2009; 119: 2408-2416.
23. Hardy J, Selkoe DJ., The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002; 297: 353-356. (Pubitemid 34790756)
24. Jack CR Jr., Knopman DS, Jagust WJ, et al,. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128.
25. Dolev I, Michaelson DM., A nontransgenic mouse model shows inducible amyloid-β (Aβ) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc Natl Acad Sci USA 2004; 101: 13909-13914. (Pubitemid 39298506)
26. Tiraboschi P, Hansen LA, Masliah E, et al,. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 2004; 62: 1977-1983. (Pubitemid 38738207)
27. Schneider JA, Arvanitakis Z, Leurgans SE, et al,. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009; 66: 200-208.